BeOne Medicines (BEIGF) Equity Ratio (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Equity Ratio data on file, last reported at 0.56 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.56, down 7.1% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.56 (down 7.1% YoY), and the FY2025 annual result was 0.53, down 5.37% from the prior year.
• Equity Ratio improved to 0.56 in Q1 2026 per BEIGF's latest filing, from 0.53 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.8 in Q4 2022 and troughed at 0.53 in Q4 2025.
• A 5-year average of 0.63 and a median of 0.6 in 2025 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2022 and 2023: Equity Ratio rose 11.31% in 2022, then fell 23.81% in 2023.
• A 5-year view of Equity Ratio shows it stood at 0.8 in 2022, then fell by 23.81% to 0.61 in 2023, then retreated by 7.64% to 0.56 in 2024, then fell by 5.37% to 0.53 in 2025, then grew by 4.5% to 0.56 in 2026.
• Business Quant data shows BEIGF's Equity Ratio at 0.56 in Q1 2026, 0.53 in Q4 2025, and 0.54 in Q3 2025.